| Right-of-use assets |
8. Right-of-use assets | | | | | | | Year ended December 31, 2024 | | Properties | | Equipment | | Total | Opening net book amount | | 328,524 | | 1,808 | | 330,332 | Depreciation charge | | (73,337) | | (677) | | (74,014) | Effect of lease modifications | | 23,940 | | — | | 23,940 | Disposals | | (7,408) | | — | | (7,408) | Assets transferred to Neurosterix Pharma Sàrl | | (230,141) | | (1,131) | | (231,272) | Closing net book amount | | 41,578 | | — | | 41,578 | | | | | | | | As of December 31, 2024 | | Properties | | Equipment | | Total | Cost | | 111,642 | | — | | 111,642 | Accumulated depreciation | | (70,064) | | — | | (70,064) | Net book value | | 41,578 | | — | | 41,578 | | | | | | | | Year ended December 31, 2025 | | Properties | | Equipment | | Total | Opening net book amount | | 41,578 | | — | | 41,578 | Depreciation charge | | (8,048) | | — | | (8,048) | Effect of lease modifications | | — | | — | | — | Disposals | | — | | — | | — | Assets transferred to Neurosterix Pharma Sàrl | | — | | — | | — | Closing net book amount | | 33,530 | | — | | 33,530 | | | | | | | | As of December 31, 2025 | | | | Properties | | Total | Cost | | | | 111,642 | | 111,642 | Accumulated depreciation | | | | (78,112) | | (78,112) | Net book value | | | | 33,530 | | 33,530 |
The gross value of the right of use assets relate to an office space rent by the Group. The cash outflows for the principal element of lease payment amounted to CHF 7,306 for the twelve-month period ended December 31, 2025 (CHF 73,688 for the twelve-month period ended December 31, 2024). The maturity analysis of lease liabilities is presented under note 3.2.
|